Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate

Scandinavian Journal of Urology

Volumn 48, Issue 3, 2014, Pages 268-275

  Thomsen, Frederik Birkebaek ^a,b   Roder, Martin Andreas ^a,b   Rathenborg, Per ^c   Brasso, Klaus ^a,b   Borre, Michael ^d   Iversen, Peter ^a,b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Abiraterone; Castration resistant prostate cancer; Enzalutamide; Post chemotherapy; Sequencing

Indexed keywords

ABIRATERONE ACETATE; ALKALINE PHOSPHATASE; ANTIANDROGEN; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN; 17-(3-PYRIDYL)-5,16-ANDROSTADIEN-3BETA-ACETATE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PHENYLTHIOHYDANTOIN; TAXOID;

ADULT; AGED; ANTIANDROGEN THERAPY; ARTICLE; CANCER GROWTH; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL PROTOCOL; CORRELATION ANALYSIS; FOLLOW UP; HUMAN; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATECTOMY; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; COHORT ANALYSIS; COMPASSIONATE USE; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; STATISTICAL MODEL; TREATMENT FAILURE;

AGED; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; COHORT STUDIES; COMPASSIONATE USE TRIALS; DISEASE-FREE SURVIVAL; HUMANS; KALLIKREINS; LINEAR MODELS; MALE; MIDDLE AGED; PHENYLTHIOHYDANTOIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84900555159     PISSN: 21681805     EISSN: 21681813     Source Type: Journal    
DOI: 10.3109/21681805.2013.860189     Document Type: Article

References (12)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
2. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
3. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54.
4. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22.
5. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
6. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-97.
7. Schalken JA. Molecular aspects of hormone-independent prostate cancer. BJU Int 2007; 100: 52-5.
8. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-48.
9. Rathkopf D, Smith M, De Bono J, Logothetis C, Shore N, De Souza P, et al. Updated interim analysis (IA) of COUAA- 302, a randomized phase III study of abirateone acetate (AA) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) without prior chemotherapy. J Clin Oncol 2013; 31(Suppl 6): Abstract 5.
10. Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013; 24: 1807-12.
11. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013; 24: 1802-7.
12. Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, et al. Enzalutamide in castrationresistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2013; Epub ahead of print.